BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21263229)

  • 1. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models.
    Kita Y; Okada M; Nakajima T; Kanamaru N; Hashimoto S; Nagasawa T; Kaneda Y; Yoshida S; Nishida Y; Nakatani H; Takao K; Kishigami C; Nishimatsu S; Sekine Y; Takamori Y; McMurray DN; De la Cruz EC; Tan EV; Abalos RM; Burgos JA; Saunderson P; Sakatani M
    Hum Vaccin; 2011; 7 Suppl():108-14. PubMed ID: 21263229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The study of novel DNA vaccines against tuberculosis: induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis.
    Okada M; Kita Y; Nakajima T; Hashimoto S; Nakatani H; Nishimatsu S; Nishida Y; Kanamaru N; Kaneda Y; Takamori Y; McMurray D; Tan EV; Cang ML; Saunderson P; Dela Cruz EC
    Hum Vaccin Immunother; 2013 Mar; 9(3):515-25. PubMed ID: 23249543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy.
    Kita Y; Hashimoto S; Nakajima T; Nakatani H; Nishimatsu S; Nishida Y; Kanamaru N; Kaneda Y; Takamori Y; McMurray D; Tan EV; Cang ML; Saunderson P; Dela Cruz EC; Okada M
    Hum Vaccin Immunother; 2013 Mar; 9(3):526-33. PubMed ID: 23249609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis.
    Okada M; Kita Y; Nakajima T; Kanamaru N; Hashimoto S; Nagasawa T; Kaneda Y; Yoshida S; Nishida Y; Nakatani H; Takao K; Kishigami C; Nishimatsu S; Sekine Y; Inoue Y; Matsumoto M; McMurray DN; De la Cruz EC; Tan EV; Abalos RM; Burgos JA; Saunderson P; Sakatani M
    Hum Vaccin; 2011; 7 Suppl():60-7. PubMed ID: 21546794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-tuberculosis immunity by cytotoxic T cells * granulysin and the development of novel vaccines (HSP-65 DNA+IL-12 DNA)].
    Okada M; Kita Y
    Kekkaku; 2010 Jun; 85(6):531-8. PubMed ID: 20662249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel prophylactic and therapeutic vaccine against tuberculosis.
    Okada M; Kita Y; Nakajima T; Kanamaru N; Hashimoto S; Nagasawa T; Kaneda Y; Yoshida S; Nishida Y; Nakatani H; Takao K; Kishigami C; Inoue Y; Matsumoto M; McMurray DN; Dela Cruz EC; Tan EV; Abalos RM; Burgos JA; Saunderson P; Sakatani M
    Vaccine; 2009 May; 27(25-26):3267-70. PubMed ID: 19200841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Therapeutic and Prophylactic Vaccine (HVJ-Envelope / Hsp65 DNA + IL-12 DNA) against Tuberculosis Using the Cynomolgus Monkey Model.
    Okada M; Kita Y; Nakajima T; Kanamaru N; Hashimoto S; Nishida Y; Nakatani H; Takao K; Kishigami C; Nishimatsu S; Sekine Y; Inoue Y; Nagasawa T; Kaneda Y; Yoshida S; Matsumoto M; Paul S; Tan EV; Cruz ECD; N McMurray D; Sakatani M
    Procedia Vaccinol; 2010; 2(1):34-39. PubMed ID: 32288910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The development of novel vaccines against tuberculosis].
    Okada M
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):356-68. PubMed ID: 18974619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB.
    Okada M; Kita Y; Nakajima T; Kanamaru N; Hashimoto S; Nagasawa T; Kaneda Y; Yoshida S; Nishida Y; Fukamizu R; Tsunai Y; Inoue R; Nakatani H; Namie Y; Yamada J; Takao K; Asai R; Asaki R; Matsumoto M; McMurray DN; Dela Cruz EC; Tan EV; Abalos RM; Burgos JA; Gelber R; Sakatani M
    Vaccine; 2007 Apr; 25(16):2990-3. PubMed ID: 17280753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis.
    Okada M; Kita Y; Nakajima T; Kanamaru N; Hashimoto S; Nagasawa T; Kaneda Y; Yoshida S; Nishida Y; Nakatani H; Takao K; Kishigami C; Nishimatsu S; Sekine Y; Inoue Y; McMurray DN; Sakatani M
    Clin Dev Immunol; 2011; 2011():549281. PubMed ID: 21437226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model.
    Okada M; Kita Y; Nakajima T; Kanamaru N; Kaneda Y; Saunderson P; Tan EV; McMurray DN
    Procedia Vaccinol; 2011; 4():42-49. PubMed ID: 32288912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model.
    Kita Y; Tanaka T; Yoshida S; Ohara N; Kaneda Y; Kuwayama S; Muraki Y; Kanamaru N; Hashimoto S; Takai H; Okada C; Fukunaga Y; Sakaguchi Y; Furukawa I; Yamada K; Inoue Y; Takemoto Y; Naito M; Yamada T; Matsumoto M; McMurray DN; Cruz EC; Tan EV; Abalos RM; Burgos JA; Gelber R; Skeiky Y; Reed S; Sakatani M; Okada M
    Vaccine; 2005 Mar; 23(17-18):2132-5. PubMed ID: 15755583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation.
    Yoshida S; Tanaka T; Kita Y; Kuwayama S; Kanamaru N; Muraki Y; Hashimoto S; Inoue Y; Sakatani M; Kobayashi E; Kaneda Y; Okada M
    Vaccine; 2006 Feb; 24(8):1191-204. PubMed ID: 16216394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccine with discontinuous T-cell epitope insertions into HSP65 scaffold as a potential means to improve immunogenicity of multi-epitope Mycobacterium tuberculosis vaccine.
    Wu M; Li M; Yue Y; Xu W
    Microbiol Immunol; 2016 Sep; 60(9):634-45. PubMed ID: 27531823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis.
    Okada M; Kita Y; Hashimoto S; Nakatani H; Nishimastu S; Kioka Y; Takami Y
    Hum Vaccin Immunother; 2017 Feb; 13(2):298-305. PubMed ID: 27960629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.
    Changhong S; Hai Z; Limei W; Jiaze A; Li X; Tingfen Z; Zhikai X; Yong Z
    Tuberculosis (Edinb); 2009 Jan; 89(1):54-61. PubMed ID: 19056317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?
    Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S
    Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.